VivoSim Labs's EBIT per Share for the
three
months ended in Dec. 2025 was €-0.88.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.21.
During the past 3 years, the average EBIT per Share Growth Rate was 18.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 21.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for VivoSim Labs's EBIT per Share or its related term are showing as below:
FRA:4OR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -511 Med: 15 Max: 34.6
Current: 18.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of VivoSim Labs was 34.60% per year. The lowest was -511.00% per year. And the median was 15.00% per year.
FRA:4OR's 3-Year EBIT Growth Rate is ranked better than 53.94% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs FRA:4OR: 18.40
VivoSim Labs's EBIT for the
three
months ended in Dec. 2025 was €-2.30 Mil.
VivoSim Labs (FRA:4OR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
VivoSim Labs EBIT per Share Related Terms
VivoSim Labs EBIT per Share Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a EBIT per Share of €1.21 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #544 out of 1181 companies in the Biotechnology industry, placing it in the top 46.1%.
Is VivoSim Labs' EBIT per Share too high?
VivoSim Labs' current EBIT per Share is €1.21. Based on the distribution chart, VivoSim Labs ranks #544 out of 1181 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EBIT per Share compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #544 out of 1181 companies for EBIT per Share. This puts VivoSim Labs in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current EBIT per Share is €1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EBIT per Share of €1.21. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current EBIT per Share is €1.21. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EBIT per Share is €1.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.
Key valuation signals for FRA:4OR:
EBIT per Share: €1.21
GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
